Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference
Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Exelixis, Inc. (NAS: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's president and chief executive officer, will present at the 33rd Annual Cowen Health Care Conference at 2:50 p.m. EST / 11:50 a.m. PST on Monday, March 4, 2013, in Boston. During the presentation, Dr. Morrissey will review the company's development plans and priorities for cabozantinib in 2013. He will also discuss the company's corporate strategy and financial outlook, and provide a general business update.
The presentation will be webcast and may be accessed via the Event Calendar page under Investors & Media at www.exelixis.com.
About Exelixis
Exelixis is a biotechnology company committed to developing small molecule therapies for the treatment of cancer. Exelixis is focusing its proprietary resources and development efforts exclusively on COMETRIQ™ (cabozantinib). Exelixis has also established a portfolio of other novel compounds that it believes have the potential to address serious unmet medical needs, many of which are being advanced by partners as part of collaborations. For more information, please visit the company's web site at www.exelixis.com.
Exelixis, Inc.
Charles Butler, 650-837-7277
Vice President, Investor Relations and Corporate Communications
cbutler@exelixis.com
KEYWORDS: United States North America California Massachusetts
INDUSTRY KEYWORDS:
The article Exelixis Announces Webcast of March 4 Presentation at the 33rd Annual Cowen Health Care Conference originally appeared on Fool.com.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.
